Medlab Clinical Overview
- Founded
-
2012
- Status
-
Public
- Employees
-
48
- Stock Symbol
-
MDC
- Share Price
-
$7.09
- (As of Wednesday Closing)
Medlab Clinical General Information
Description
Medlab Clinical Ltd is a medical research and development company. It is engaged in researching and formulating novel biotherapeutics to improve health outcomes in early to moderate stage chronic diseases such as chronic kidney disease, pre-diabetes, and obesity. Some of the company's nutraceutical products are Multibiotic, Mg Optima Relax, NRGBiotic, NanoCelle D3, SB 5B and others. The principal segments of the group are Nutraceutical which includes the sale of nutraceutical products; and Pharmaceutical research. It generates the majority of the revenue from the sale of nutraceutical products. The business operations of the firm are carried out from Australia.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
ASX
Primary Office
- 11-13 Lord Strret Botany
- Building A, Unit A5 A6, Botany Quarter
- Sydney, New South Wales 2019
- Australia
+61 (02) 0000 0000
Medlab Clinical Timeline
Medlab Clinical Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $7.09 | $7.38 | $4.48 - $22.22 | $16.2M | 2.28M | 1.47K |
Medlab Clinical Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2022 | FY 2022 30-Jun-2022 | FY 2021 30-Jun-2021 | FY 2020 30-Jun-2020 |
|---|---|---|---|---|
| EV | 8,272 | 8,272 | 28,278 | 23,025 |
| Revenue | 3,280 | 1,908 | ||
| EBITDA | (8,511) | (8,310) | ||
| Net Income | (9,188) | (8,975) | ||
| Total Assets | 15,512 | 12,223 | ||
| Total Debt | 1,274 | 1,604 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Medlab Clinical Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Medlab Clinical Patents
Medlab Clinical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021903495-A0 | Fabric products | Pending | 02-Nov-2021 | ||
| AU-2021902932-A0 | Probiotic compositions and uses thereof | Pending | 10-Sep-2021 | ||
| AU-2021901053-A0 | Compositions | Pending | 12-Apr-2021 | ||
| AU-2021900459-A0 | Combination therapy | Pending | 22-Feb-2021 | ||
| AU-2020903959-A0 | Fabric products | Pending | 30-Oct-2020 |
Medlab Clinical Executive Team (4)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Sean Hall | Chief Executive Officer & Managing Director | ||
| Kerem Kaya | Chief Financial Officer & Company Secretary | ||
| Ian Curtinsmith | Chief Information Officer |
Medlab Clinical Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
